



BRITISH COLUMBIA
CENTRE *for* EXCELLENCE
in HIV/AIDS

BC HIV Treatment Program

Monthly Report
May 2025



FOREWORD

The British Columbia Centre for Excellence in HIV/AIDS (BC-CfE) is a provincial treatment and research program, with the mandate to improve the health of people living with HIV (“PLWH”), and those at elevated risk of acquiring HIV in British Columbia (BC), by advancing and promoting programs for treatment and prevention of HIV, and related conditions, guided by Treatment as Prevention® (TasP®) principles. Funded by the BC’s Ministry of Health, through the province’s PharmaCare Program, the BC-CfE’s Drug Treatment Programs provide medications for HIV treatment, prevention, and select related conditions, at no charge, to medically eligible BC residents living with HIV, or at elevated risk of HIV acquisition. The provision of these medications are based on guidelines developed by the BC-CfE’s Committee for Drug Evaluation and Therapy (CDET) and program consideration.

A key component of the BC-CfE’s mandate is to monitor and evaluate its HIV Treatment Program, reporting on a regular basis and providing essential information to BC’s health authorities, treating clinicians, and the community at large. This HIV Treatment Program Report provides an overview of the use of antiretroviral medications in BC for the treatment of HIV, common drug combinations, key monitoring parameters, and distribution of program participants throughout the province.

Figures and graphs in this document are best viewed in colour.

Please note that any comments or queries regarding this report should be forwarded to info@bccfe.ca.

BC Centre for Excellence in HIV/AIDS Drug Treatment Programs

St. Paul’s Hospital
687 - 1081 Burrard Street
Vancouver, BC
V6Z 1Y6

Tel: 604.806.8515
Fax: 604.806.9044

Website: www.bccfe.ca
Email: info@bccfe.ca

Funding for the BC Centre for Excellence in HIV/AIDS is provided through BC’s PharmaCare and Ministry of Health.

DISCLAIMER: All information presented in this report is generated from a secure, live database maintained by the BC-CfE. Privacy and confidentiality are matters which are taken very seriously and strict rules and procedures are applied to ensure that the information stored is secure.

Figures and tables provided in this report represent the best estimates at the time the document was generated, and may be subject to change. Please be advised that the information in this document is provided in good faith and is derived from sources understood to be accurate and up-to-date at the report’s date of publication.

© 2026 BC Centre for Excellence in HIV/AIDS



TABLE OF CONTENTS

1. List of Figures

- 1.1 Distribution of Participants on Antiretroviral Treatment in British Columbia by Health Authority
- 1.2 Distribution of Participants in HIV Treatment Program by Regimen Category
- 1.3 Distribution of Participants in HIV Treatment Program by Regimen Category
- 1.4 Distribution of Participants on Nucleos(t)ide Analogue Reverse Transcriptase Inhibitors by INGREDIENT
- 1.5 Number of Participants on Nucleos(t)ide Analogue Reverse Transcriptase Inhibitors by INGREDIENT
- 1.6 Distribution of Participants on Protease Inhibitors by INGREDIENT
- 1.7 Number of Participants on Protease Inhibitors by INGREDIENT
- 1.8 Distribution of Participants on Non-Nucleoside Analogue Reverse Transcriptase Inhibitors by INGREDIENT
- 1.9 Number of Participants on Non-Nucleoside Analogue Reverse Transcriptase Inhibitors by INGREDIENT
- 1.10 Distribution of Participants on Integrase Inhibitors by INGREDIENT
- 1.11 Number of Participants on Integrase Inhibitors by INGREDIENT
- 1.12 Distribution of Participants on Other Antiretroviral Drug Classes by INGREDIENT
- 1.13 Number of Participants on Other Antiretroviral Drug Classes by INGREDIENT
- 1.14 Distribution of Participants on Antiretroviral Treatment by Number of Antiretrovirals (graph)
- 1.15 Distribution of Participants on Antiretroviral Treatment by Number of Antiretrovirals (table)
- 1.16 Percent Distribution of Active Participants by CD4 Count
- 1.17 Distribution of Active Participants by CD4 Count
- 1.18 Initial Regimen Composition for Antiretroviral Treatment Naïve Participants Starting Treatment (graph)
- 1.19 Initial Regimen Composition for Antiretroviral Treatment Naïve Participants Starting Treatment (table)
- 1.20 Pre-entry CD4 for Antiretroviral Treatment Naïve Participants in the HIV Treatment Program (graph)
- 1.21 Pre-entry CD4 for Antiretroviral Treatment Naïve Participants in the HIV Treatment Program (table)
- 1.22 Antiretroviral Resistance by Drug Class Among Participants on Antiretroviral Treatment (graph)
- 1.23 Antiretroviral Resistance by Drug Class Among Participants on Antiretroviral Treatment (table)
- 1.24 Active Participants by number of Antiretroviral Drug Classes with Resistance (graph)
- 1.25 Active Participants by number of Antiretroviral Drug Classes with Resistance (table)

2. List of Tables

- 2.1 Active participants by Year of Program Initiation (1987 - 2025) - as of January 2025
- 2.2 HIV Viral Load (copies/mL) and CD4 (cells/ μ L) for Participants on Antiretroviral Treatment
- 2.3 BC-CfE HIV Treatment Program Enrolment

3. Distribution of HIV Treatment Program Active Participants

- 3.1 Provincial Health Authorities
- 3.2 Interior Health Authority & Kelowna
- 3.3 Fraser Health Authority & Surrey
- 3.4 Vancouver Coastal Health Authority & Vancouver
- 3.5 Vancouver Island Health Authority & Victoria
- 3.6 Northern Health Authority & Prince George

TABLE OF CONTENTS (continued)

4. Health Authority Tables

INTERIOR HEALTH

- 4.1 Distribution of Participants by Age & Sex at Birth
- 4.2 Distribution of Participants by Program Duration
- 4.3 Distribution of Antiretroviral Treatment Prescribers

FRASER HEALTH

- 4.4 Distribution of Participants by Age & Sex at Birth
- 4.5 Distribution of Participants by Program Duration
- 4.6 Distribution of Antiretroviral Treatment Prescribers

VANCOUVER COASTAL

- 4.7 Distribution of Participants by Age & Sex at Birth
- 4.8 Distribution of Participants by Program Duration
- 4.9 Distribution of Antiretroviral Treatment Prescribers

VANCOUVER ISLAND

- 4.10 Distribution of Participants by Age & Sex at Birth
- 4.11 Distribution of Participants by Program Duration
- 4.12 Distribution of Antiretroviral Treatment Prescribers

NORTHERN HEALTH


- 4.13 Distribution of Participants by Age & Sex at Birth
- 4.14 Distribution of Participants by Program Duration
- 4.15 Distribution of Antiretroviral Treatment Prescribers

INDIGENOUS PARTICIPANTS

- 4.16 Distribution of Indigenous Participants by Health Service Delivery Area and Sex at Birth



1.1 Distribution of Participants on Antiretroviral Treatment in British Columbia by Health Authority
May 2025
N = 7705




Health Authority	Male	Female	All
FRASER	1616	506	2122
VANCOUVER ISLAND	893	175	1068
VANCOUVER COASTAL	3197	445	3642
INTERIOR	503	118	621
NORTHERN	164	79	243
	6373	1323	7696
Unknown/not stated			9
Total			7705

On antiretroviral treatment is defined as being on treatment in the current month
Unknown/not stated is defined as being on treatment in the current month, and city of residence is unknown
Male & Female refer to Sex assigned at birth



1.2 Distribution of Participants in HIV Treatment Program by Regimen Category
May 2020 - May 2025



1.3 Distribution of Participants in HIV Treatment Program by Regimen Category

MON-YYYY	Total	INSTI		Boosted PI		NNRTI		2 drugs from 2 classes		≥3 drugs from ≥3 classes		Other	
		n	%	n	%	n	%	n	%	n	%	n	%
JUN-2023	7599	4788	63.0	675	8.9	625	8.2	819	10.8	627	8.3	65	0.9
JUL-2023	7577	4758	62.8	662	8.7	626	8.3	842	11.1	628	8.3	61	0.8
AUG-2023	7600	4773	62.8	643	8.5	621	8.2	864	11.4	632	8.3	67	0.9
SEP-2023	7609	4793	63.0	639	8.4	616	8.1	879	11.6	617	8.1	65	0.9
OCT-2023	7610	4808	63.2	615	8.1	611	8.0	897	11.8	618	8.1	61	0.8
NOV-2023	7612	4799	63.0	611	8.0	599	7.9	918	12.1	624	8.2	61	0.8
DEC-2023	7603	4808	63.2	593	7.8	596	7.8	936	12.3	614	8.1	56	0.7
JAN-2024	7642	4856	63.5	583	7.6	585	7.7	952	12.5	609	8.0	57	0.7
FEB-2024	7647	4861	63.6	564	7.4	586	7.7	971	12.7	609	8.0	56	0.7
MAR-2024	7636	4846	63.5	543	7.1	580	7.6	991	13.0	618	8.1	58	0.8
APR-2024	7670	4884	63.7	538	7.0	570	7.4	1000	13.0	621	8.1	57	0.7
MAY-2024	7687	4902	63.8	536	7.0	566	7.4	1023	13.3	607	7.9	53	0.7
JUN-2024	7687	4910	63.9	526	6.8	556	7.2	1033	13.4	606	7.9	56	0.7
JUL-2024	7718	4938	64.0	520	6.7	541	7.0	1060	13.7	605	7.8	54	0.7
AUG-2024	7709	4933	64.0	505	6.6	537	7.0	1081	14.0	602	7.8	51	0.7
SEP-2024	7697	4911	63.8	484	6.3	530	6.9	1124	14.6	595	7.7	53	0.7
OCT-2024	7725	4938	63.9	467	6.0	512	6.6	1167	15.1	593	7.7	48	0.6
NOV-2024	7703	4946	64.2	464	6.0	490	6.4	1176	15.3	581	7.5	46	0.6
DEC-2024	7720	4949	64.1	456	5.9	479	6.2	1199	15.5	588	7.6	49	0.6
JAN-2025	7739	4959	64.1	437	5.6	478	6.2	1234	15.9	586	7.6	45	0.6
FEB-2025	7696	4929	64.0	419	5.4	460	6.0	1264	16.4	577	7.5	47	0.6
MAR-2025	7689	4921	64.0	408	5.3	453	5.9	1291	16.8	572	7.4	44	0.6
APR-2025	7719	4947	64.1	394	5.1	432	5.6	1320	17.1	584	7.6	42	0.5
MAY-2025	7705	4911	63.7	386	5.0	423	5.5	1369	17.8	573	7.4	43	0.6

n is number of participants on the specified regimen class in the specified month


% is ratio of **n** and total number of participants on antiretroviral treatment in the specified month

INSTI: Integrase Inhibitor, **PI:** Protease Inhibitor, **NNRTI:** Non-Nucleoside Analogue Reverse Transcriptase Inhibitor,

N(t)RTI: Nucleos(t)ide Analogue Reverse Transcriptase Inhibitor



1.4 Distribution of Participants on Nucleos(t)ide Analogue Reverse Transcriptase Inhibitors by INGREDIENT
May 2020 - May 2025




1.5 Number of Participants on Nucleos(t)ide Analogue Reverse Transcriptase Inhibitors by INGREDIENT

MON-YYYY	Total Participants	abacavir		emtricitabine		lamivudine		tenofovir <TAF>		tenofovir <TDF>		zidovudine	
		n	%	n	%	n	%	n	%	n	%	n	%
JUN-2023	7460	2008	26.9	4533	60.8	2934	39.3	3655	49.0	1002	13.4	14	0.2
JUL-2023	7438	1966	26.4	4530	60.9	2917	39.2	3678	49.5	985	13.2	14	0.2
AUG-2023	7467	1935	25.9	4561	61.1	2909	39.0	3717	49.8	969	13.0	14	0.2
SEP-2023	7478	1910	25.5	4578	61.2	2902	38.8	3746	50.1	954	12.8	13	0.2
OCT-2023	7474	1895	25.4	4573	61.2	2904	38.9	3766	50.4	935	12.5	14	0.2
NOV-2023	7474	1866	25.0	4585	61.4	2891	38.7	3783	50.6	918	12.3	15	0.2
DEC-2023	7464	1831	24.5	4595	61.6	2874	38.5	3820	51.2	895	12.0	13	0.2
JAN-2024	7502	1831	24.4	4633	61.8	2881	38.4	3866	51.5	890	11.9	13	0.2
FEB-2024	7504	1795	23.9	4641	61.9	2868	38.2	3896	51.9	864	11.5	13	0.2
MAR-2024	7493	1759	23.5	4656	62.1	2845	38.0	3927	52.4	844	11.3	13	0.2
APR-2024	7525	1742	23.2	4690	62.3	2844	37.8	3968	52.7	843	11.2	13	0.2
MAY-2024	7544	1706	22.6	4734	62.8	2822	37.4	4018	53.3	832	11.0	12	0.2
JUN-2024	7544	1691	22.4	4738	62.8	2817	37.3	4047	53.7	801	10.6	13	0.2
JUL-2024	7570	1667	22.0	4763	62.9	2812	37.2	4077	53.9	800	10.6	13	0.2
AUG-2024	7563	1633	21.6	4771	63.1	2796	37.0	4097	54.2	782	10.3	13	0.2
SEP-2024	7551	1600	21.2	4769	63.2	2797	37.0	4113	54.5	768	10.2	13	0.2
OCT-2024	7577	1556	20.5	4810	63.5	2789	36.8	4170	55.0	754	10.0	13	0.2
NOV-2024	7555	1499	19.8	4821	63.8	2744	36.3	4193	55.5	739	9.8	11	0.2
DEC-2024	7572	1481	19.6	4835	63.9	2756	36.4	4223	55.8	734	9.7	11	0.2
JAN-2025	7591	1431	18.9	4873	64.2	2740	36.1	4273	56.3	721	9.5	10	0.1
FEB-2025	7547	1370	18.2	4860	64.4	2698	35.8	4280	56.7	701	9.3	8	0.1
MAR-2025	7537	1335	17.7	4869	64.6	2680	35.6	4312	57.2	684	9.1	8	0.1
APR-2025	7557	1304	17.3	4909	65.0	2664	35.3	4374	57.9	655	8.7	6	0.1
MAY-2025	7537	1242	16.5	4894	64.9	2654	35.2	4373	58.0	630	8.4	7	0.1

n is defined as number of participants on antiretroviral treatment which contains the INGREDIENT;
% is calculated as ratio of "n" and number of participants whose treatment is of the given antiretroviral drug class



1.6 Distribution of Participants on Protease Inhibitors by INGREDIENT
May 2020 - May 2025




1.7 Number of Participants on Protease Inhibitors by INGREDIENT

MON-YYYY	Total Participants	atazanavir		darunavir		lopinavir		ritonavir		tipranavir	
		n	%	n	%	n	%	n	%	n	%
JUN-2023	1267	294	23.2	936	73.9	39	3.1	1	0.1	1	0.1
JUL-2023	1247	283	22.7	927	74.3	38	3.1	1	0.1	1	0.1
AUG-2023	1225	276	22.5	914	74.6	36	2.9	0	0.0	0	0.0
SEP-2023	1214	271	22.3	909	74.9	35	2.9	0	0.0	0	0.0
OCT-2023	1198	273	22.8	893	74.5	35	2.9	0	0.0	0	0.0
NOV-2023	1184	260	22.0	890	75.2	35	3.0	0	0.0	0	0.0
DEC-2023	1156	248	21.5	876	75.8	33	2.9	0	0.0	0	0.0
JAN-2024	1138	241	21.2	866	76.1	33	2.9	0	0.0	0	0.0
FEB-2024	1111	229	20.6	852	76.7	31	2.8	0	0.0	0	0.0
MAR-2024	1094	225	20.6	840	76.8	30	2.7	0	0.0	0	0.0
APR-2024	1088	224	20.6	835	76.8	31	2.9	0	0.0	0	0.0
MAY-2024	1081	221	20.4	828	76.6	33	3.1	0	0.0	0	0.0
JUN-2024	1059	214	20.2	813	76.8	33	3.1	0	0.0	0	0.0
JUL-2024	1052	216	20.5	805	76.5	33	3.1	0	0.0	0	0.0
AUG-2024	1021	208	20.4	784	76.8	31	3.0	0	0.0	0	0.0
SEP-2024	1001	203	20.3	772	77.1	27	2.7	0	0.0	0	0.0
OCT-2024	977	197	20.2	754	77.2	27	2.8	0	0.0	0	0.0
NOV-2024	957	190	19.9	742	77.5	28	2.9	0	0.0	0	0.0
DEC-2024	947	184	19.4	738	77.9	26	2.8	0	0.0	0	0.0
JAN-2025	922	177	19.2	726	78.7	23	2.5	0	0.0	0	0.0
FEB-2025	891	168	18.9	700	78.6	24	2.7	0	0.0	0	0.0
MAR-2025	875	167	19.1	686	78.4	24	2.7	0	0.0	0	0.0
APR-2025	860	153	17.8	684	79.5	24	2.8	0	0.0	0	0.0
MAY-2025	840	151	18.0	666	79.3	24	2.9	0	0.0	0	0.0

n is defined as number of participants on antiretroviral treatment which contains the INGREDIENT;
 % is calculated as ratio of "n" and number of participants whose treatment is of the given antiretroviral drug class
 Ritonavir - greater than 400 mg total daily dose

**1.8 Distribution of Participants on Non-Nucleoside Analogue Reverse Transcriptase Inhibitors by INGREDIENT
May 2020 - May 2025**




1.9 Number of Participants on Non-Nucleoside Analogue Reverse Transcriptase Inhibitors by INGREDIENT

MON-YYYY	Total Participants	doravirine n %	efavirenz n %	etravirine n %	nevirapine n %	rilpivirine n %
JUN-2023	954	224 23.5	228 23.9	96 10.1	230 24.1	180 18.9
JUL-2023	953	235 24.7	222 23.3	94 9.9	225 23.6	178 18.7
AUG-2023	951	238 25.0	222 23.3	91 9.6	223 23.5	182 19.1
SEP-2023	938	236 25.2	218 23.2	88 9.4	220 23.5	177 18.9
OCT-2023	932	238 25.5	216 23.2	89 9.6	220 23.6	173 18.6
NOV-2023	928	242 26.1	209 22.5	88 9.5	219 23.6	173 18.6
DEC-2023	929	250 26.9	205 22.1	87 9.4	213 22.9	176 19.0
JAN-2024	921	250 27.1	200 21.7	83 9.0	208 22.6	181 19.7
FEB-2024	919	257 28.0	192 20.9	82 8.9	207 22.5	182 19.8
MAR-2024	914	260 28.5	190 20.8	80 8.8	205 22.4	181 19.8
APR-2024	915	261 28.5	190 20.8	82 9.0	203 22.2	180 19.7
MAY-2024	906	262 28.9	186 20.5	80 8.8	205 22.6	175 19.3
JUN-2024	893	262 29.3	182 20.4	79 8.9	198 22.2	172 19.3
JUL-2024	890	270 30.3	176 19.8	78 8.8	194 21.8	172 19.3
AUG-2024	879	272 30.9	174 19.8	78 8.9	187 21.3	171 19.5
SEP-2024	886	275 31.0	172 19.4	76 8.6	185 20.9	179 20.2
OCT-2024	871	283 32.5	168 19.3	72 8.3	177 20.3	175 20.1
NOV-2024	850	287 33.8	162 19.1	70 8.2	159 18.7	173 20.4
DEC-2024	844	303 35.9	156 18.5	71 8.4	149 17.7	167 19.8
JAN-2025	844	309 36.6	157 18.6	67 7.9	143 16.9	172 20.4
FEB-2025	834	306 36.7	156 18.7	64 7.7	136 16.3	173 20.7
MAR-2025	823	311 37.8	147 17.9	62 7.5	132 16.0	173 21.0
APR-2025	818	317 38.8	137 16.8	61 7.5	128 15.7	177 21.6
MAY-2025	809	313 38.7	129 16.0	60 7.4	126 15.6	181 22.4

n is defined as number of participants on antiretroviral treatment which contains the INGREDIENT;
% is calculated as ratio of "n" and number of participants whose treatment is of the given antiretroviral drug class

1.10 Distribution of Participants on Integrase Inhibitors by INGREDIENT
May 2020 - May 2025






1.11 Number of Participants on Integrase Inhibitors by INGREDIENT

MON-YYYY	Total Participants	bictegravir n %	cabotegravir n %	dolutegravir n %	elvitegravir n %	raltegravir n %
JUN-2023	6204	3197 51.5	5 0.1	2509 40.4	248 4.0	267 4.3
JUL-2023	6201	3218 51.9	5 0.1	2499 40.3	247 4.0	256 4.1
AUG-2023	6240	3258 52.2	7 0.1	2495 40.0	245 3.9	253 4.1
SEP-2023	6263	3289 52.5	8 0.1	2500 39.9	238 3.8	249 4.0
OCT-2023	6294	3298 52.4	7 0.1	2523 40.1	241 3.8	248 3.9
NOV-2023	6311	3327 52.7	9 0.1	2518 39.9	233 3.7	244 3.9
DEC-2023	6330	3365 53.2	13 0.2	2506 39.6	226 3.6	237 3.7
JAN-2024	6389	3418 53.5	16 0.3	2520 39.4	224 3.5	234 3.7
FEB-2024	6417	3453 53.8	15 0.2	2516 39.2	219 3.4	231 3.6
MAR-2024	6435	3498 54.4	17 0.3	2500 38.9	220 3.4	225 3.5
APR-2024	6483	3545 54.7	17 0.3	2497 38.5	216 3.3	225 3.5
MAY-2024	6511	3586 55.1	19 0.3	2488 38.2	213 3.3	222 3.4
JUN-2024	6528	3614 55.4	21 0.3	2488 38.1	207 3.2	218 3.3
JUL-2024	6584	3650 55.4	25 0.4	2500 38.0	212 3.2	213 3.2
AUG-2024	6593	3683 55.9	26 0.4	2487 37.7	204 3.1	207 3.1
SEP-2024	6610	3700 56.0	32 0.5	2495 37.8	200 3.0	205 3.1
OCT-2024	6680	3757 56.2	34 0.5	2508 37.5	198 3.0	199 3.0
NOV-2024	6681	3791 56.7	33 0.5	2487 37.2	191 2.9	193 2.9
DEC-2024	6720	3819 56.8	33 0.5	2521 37.5	185 2.8	187 2.8
JAN-2025	6762	3866 57.2	36 0.5	2525 37.3	185 2.7	179 2.7
FEB-2025	6754	3883 57.5	41 0.6	2495 36.9	183 2.7	176 2.6
MAR-2025	6767	3913 57.8	48 0.7	2481 36.7	181 2.7	175 2.6
APR-2025	6834	3985 58.3	49 0.7	2488 36.4	176 2.6	167 2.4
MAY-2025	6840	3987 58.3	57 0.8	2478 36.2	174 2.5	165 2.4

n is defined as number of participants on antiretroviral treatment which contains the INGREDIENT;
% is calculated as ratio of "n" and number of participants whose treatment is of the given antiretroviral drug class



1.12 Distribution of Participants on Other Antiretroviral Drug Classes by INGREDIENT
May 2020 - May 2025






1.13 Number of Participants on Other Antiretroviral Drug Classes by INGREDIENT

MON-YYYY	Total Participants	fostemsavir		maraviroc		lenacapavir	
		n	%	n	%	n	%
JUN-2023	20	2	10.0	18	90.0	0	0.0
JUL-2023	20	2	10.0	18	90.0	0	0.0
AUG-2023	20	2	10.0	18	90.0	0	0.0
SEP-2023	20	2	10.0	18	90.0	0	0.0
OCT-2023	20	2	10.0	18	90.0	1	5.0
NOV-2023	19	1	5.3	17	89.5	1	5.3
DEC-2023	19	2	10.5	16	84.2	1	5.3
JAN-2024	21	2	9.5	18	85.7	1	4.8
FEB-2024	21	2	9.5	18	85.7	1	4.8
MAR-2024	21	3	14.3	17	81.0	2	9.5
APR-2024	22	2	9.1	18	81.8	2	9.1
MAY-2024	19	2	10.5	15	79.0	2	10.5
JUN-2024	21	2	9.5	17	81.0	2	9.5
JUL-2024	21	2	9.5	17	81.0	2	9.5
AUG-2024	21	2	9.5	17	81.0	2	9.5
SEP-2024	20	2	10.0	16	80.0	2	10.0
OCT-2024	20	2	10.0	15	75.0	3	15.0
NOV-2024	20	2	10.0	16	80.0	2	10.0
DEC-2024	20	2	10.0	16	80.0	2	10.0
JAN-2025	20	2	10.0	16	80.0	2	10.0
FEB-2025	19	2	10.5	15	79.0	2	10.5
MAR-2025	19	2	10.5	15	79.0	2	10.5
APR-2025	19	2	10.5	15	79.0	2	10.5
MAY-2025	17	2	11.8	14	82.4	1	5.9

n is defined as number of participants on antiretroviral treatment which contains the INGREDIENT;
 % is calculated as ratio of "n" and number of participants whose treatment is of the given antiretroviral drug class
 Both lenacapavir and fostemsavir are currently not on BC-CfE Formulary



1.14 Distribution of Participants on Antiretroviral Treatment by Number of Antiretrovirals
May 2020 - May 2025




1.15 Distribution of Participants on Antiretroviral Treatment by Number of Antiretrovirals

MON-YYYY	Total Participants	1 drug		2 drugs		3 drugs		4 drugs		5 or more drugs	
		n	%	n	%	n	%	n	%	n	%
JUN-2023	7599	2	0.0	819	10.8	6299	82.9	438	5.8	41	0.5
JUL-2023	7577	2	0.0	842	11.1	6253	82.5	440	5.8	40	0.5
AUG-2023	7600	2	0.0	864	11.4	6240	82.1	448	5.9	46	0.6
SEP-2023	7609	2	0.0	879	11.6	6250	82.1	432	5.7	46	0.6
OCT-2023	7610	2	0.0	897	11.8	6237	82.0	433	5.7	41	0.5
NOV-2023	7612	2	0.0	918	12.1	6210	81.6	441	5.8	41	0.5
DEC-2023	7603	2	0.0	936	12.3	6191	81.4	434	5.7	40	0.5
JAN-2024	7642	2	0.0	952	12.5	6214	81.3	432	5.7	42	0.6
FEB-2024	7647	3	0.0	971	12.7	6198	81.1	436	5.7	39	0.5
MAR-2024	7636	2	0.0	991	13.0	6159	80.7	440	5.8	44	0.6
APR-2024	7670	2	0.0	1001	13.1	6184	80.6	437	5.7	46	0.6
MAY-2024	7687	2	0.0	1024	13.3	6188	80.5	434	5.7	39	0.5
JUN-2024	7687	1	0.0	1034	13.5	6181	80.4	429	5.6	42	0.6
JUL-2024	7718	2	0.0	1061	13.8	6184	80.1	434	5.6	37	0.5
AUG-2024	7709	2	0.0	1082	14.0	6155	79.8	431	5.6	39	0.5
SEP-2024	7697	2	0.0	1125	14.6	6101	79.3	426	5.5	43	0.6
OCT-2024	7725	1	0.0	1169	15.1	6087	78.8	427	5.5	41	0.5
NOV-2024	7703	1	0.0	1177	15.3	6069	78.8	417	5.4	39	0.5
DEC-2024	7720	2	0.0	1200	15.5	6054	78.4	424	5.5	40	0.5
JAN-2025	7739	2	0.0	1235	16.0	6047	78.1	416	5.4	39	0.5
FEB-2025	7696	2	0.0	1265	16.4	5977	77.7	414	5.4	38	0.5
MAR-2025	7689	4	0.1	1292	16.8	5942	77.3	414	5.4	37	0.5
APR-2025	7719	3	0.0	1321	17.1	5939	76.9	419	5.4	37	0.5
MAY-2025	7705	4	0.1	1370	17.8	5882	76.3	410	5.3	39	0.5

n is the number of individual drugs in antiretroviral treatment regimen (excluding low dose ritonavir and cobicistat used for pharmacokinetic boosting)



1.16 Percent Distribution of Active Participants by CD4 Count
May 2020 - May 2025





1.17 Distribution of Active Participants by CD4 Count

Month	# of Pts with CD4: Unreported	# of Pts with CD4: < 200	# of Pts with CD4: 200 - 349	# of Pts with CD4: 350 - 500	# of Pts with CD4: > 500
JUN-2023	1199	247	554	963	3827
JUL-2023	1233	239	578	927	3805
AUG-2023	1277	254	560	943	3767
SEP-2023	1330	243	547	951	3744
OCT-2023	1380	242	543	943	3727
NOV-2023	1416	237	542	937	3689
DEC-2023	1459	237	530	917	3703
JAN-2024	1496	238	529	916	3679
FEB-2024	1535	242	503	911	3673
MAR-2024	1567	255	498	924	3649
APR-2024	1612	253	486	944	3627
MAY-2024	1647	248	486	923	3661
JUN-2024	1686	247	493	886	3679
JUL-2024	1748	248	493	912	3681
AUG-2024	1793	251	491	910	3659
SEP-2024	1812	241	489	935	3638
OCT-2024	1847	243	499	948	3624
NOV-2024	1882	234	505	917	3652
DEC-2024	1911	232	508	928	3658
JAN-2025	1940	233	509	939	3650
FEB-2025	1959	223	511	930	3640
MAR-2025	1981	225	508	934	3620
APR-2025	2022	230	500	903	3666
MAY-2025	2048	229	492	876	3652


CD4 value (cells/μL) as per the most recent test within the past 12 months

CD4 Unreported: CD4 not tested or reported within the past 12 months

Active Participants are participants with antiretroviral treatment in the month based on dispensing record



1.18 Initial Regimen Composition for Antiretroviral Treatment Naïve Participants Starting Treatment
May 2020 - May 2025




1.19 Initial Regimen Composition for Antiretroviral Treatment Naïve Participants Starting Treatment

MON-YYYY	Total	INSTI		Boosted PI		NNRTI		2 drugs from 2 classes		≥3 drugs from ≥3 classes		Other	
		2 N(t)RTIs n	%	2 N(t)RTIs n	%	2 N(t)RTIs n	%	n	%	n	%	n	%
JUN-2023	17	17	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
JUL-2023	11	8	72.7	0	0.0	0	0.0	0	0.0	3	27.3	0	0.0
AUG-2023	13	12	92.3	0	0.0	0	0.0	0	0.0	1	7.7	0	0.0
SEP-2023	5	5	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
OCT-2023	10	9	90.0	0	0.0	0	0.0	1	10.0	0	0.0	0	0.0
NOV-2023	9	7	77.8	0	0.0	0	0.0	1	11.1	1	11.1	0	0.0
DEC-2023	13	12	92.3	0	0.0	0	0.0	0	0.0	1	7.7	0	0.0
JAN-2024	11	9	81.8	0	0.0	0	0.0	0	0.0	2	18.2	0	0.0
FEB-2024	11	11	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
MAR-2024	13	12	92.3	0	0.0	0	0.0	0	0.0	1	7.7	0	0.0
APR-2024	20	18	90.0	0	0.0	0	0.0	0	0.0	2	10.0	0	0.0
MAY-2024	16	16	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
JUN-2024	23	22	95.7	0	0.0	0	0.0	0	0.0	1	4.3	0	0.0
JUL-2024	10	10	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
AUG-2024	15	15	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
SEP-2024	7	7	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
OCT-2024	15	15	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
NOV-2024	9	8	88.9	0	0.0	1	11.1	0	0.0	0	0.0	0	0.0
DEC-2024	10	10	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
JAN-2025	14	14	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
FEB-2025	9	9	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
MAR-2025	12	12	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
APR-2025	12	12	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
MAY-2025	17	17	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0

INSTI: Integrase Inhibitor, **PI:** Protease Inhibitor, **NNRTI:** Non-Nucleoside Analogue Reverse Transcriptase Inhibitor, **N(t)RTI:** Nucleos(t)ide Analogue Reverse Transcriptase Inhibitor
n is number of participants on the specified regimen category in the specified month
% is ratio of n and total number of participants initiating antiretroviral treatment in the specified month



1.20 Pre-entry CD4 for Antiretroviral Treatment Naïve Participants in the HIV Treatment Program
May 2020 - May 2025




1.21 Pre-entry CD4 for Antiretroviral Treatment Naive Participants in the HIV Treatment Program

MON-YYYY	# of First Starts	# of Pts with CD4: Unreported		# of Pts with CD4: < 200		# of Pts with CD4: 200 - 349		# of Pts with CD4: 350 - 500		# of Pts with CD4: > 500	
		n	%	n	%	n	%	n	%	n	%
JUN-2023	17	0	0.0	6	35.3	3	17.7	2	11.8	6	35.3
JUL-2023	11	0	0.0	3	27.3	3	27.3	2	18.2	3	27.3
AUG-2023	13	2	15.4	3	23.1	4	30.8	2	15.4	2	15.4
SEP-2023	5	0	0.0	2	40.0	0	0.0	0	0.0	3	60.0
OCT-2023	10	1	10.0	1	10.0	3	30.0	2	20.0	3	30.0
NOV-2023	9	1	11.1	2	22.2	0	0.0	2	22.2	4	44.4
DEC-2023	13	1	7.7	1	7.7	3	23.1	0	0.0	8	61.5
JAN-2024	11	1	9.1	4	36.4	2	18.2	1	9.1	3	27.3
FEB-2024	11	1	9.1	3	27.3	4	36.4	2	18.2	1	9.1
MAR-2024	13	2	15.4	5	38.5	1	7.7	1	7.7	4	30.8
APR-2024	20	0	0.0	4	20.0	6	30.0	1	5.0	9	45.0
MAY-2024	16	1	6.3	5	31.3	3	18.8	1	6.3	6	37.5
JUN-2024	23	0	0.0	2	8.7	10	43.5	4	17.4	7	30.4
JUL-2024	10	1	10.0	1	10.0	3	30.0	3	30.0	2	20.0
AUG-2024	15	0	0.0	5	33.3	4	26.7	3	20.0	3	20.0
SEP-2024	7	0	0.0	1	14.3	4	57.1	1	14.3	1	14.3
OCT-2024	15	0	0.0	6	40.0	3	20.0	3	20.0	3	20.0
NOV-2024	9	0	0.0	3	33.3	3	33.3	2	22.2	1	11.1
DEC-2024	10	0	0.0	4	40.0	2	20.0	2	20.0	2	20.0
JAN-2025	14	0	0.0	6	42.9	2	14.3	5	35.7	1	7.1
FEB-2025	9	0	0.0	2	22.2	1	11.1	3	33.3	3	33.3
MAR-2025	12	1	8.3	5	41.7	2	16.7	2	16.7	2	16.7
APR-2025	12	1	8.3	3	25.0	2	16.7	2	16.7	4	33.3
MAY-2025	17	1	5.9	6	35.3	3	17.7	5	29.4	2	11.8

First Starts defined as participants starting antiretroviral treatment in the specified month for the first time (antiretroviral treatment naive)
Pre-entry CD4 (cells/ μ L) is defined as most recent CD4 test before antiretroviral treatment start

1.22 Antiretroviral Resistance by Drug Class Among Participants on Antiretroviral Treatment
May 2020 - May 2025



1.23 Antiretroviral Resistance by Drug Class Among Participants on Antiretroviral Treatment

MON-YYYY	On Antiretroviral (ARV) Treatment	Ever Tested	NNRTI		N(t)RTI		PI		INSTI	
			n	%	n	%	n	%	n	%
JUN-2023	7577	6441	1312	20.4	1672	26.0	561	8.7	106	1.7
JUL-2023	7555	6417	1313	20.5	1678	26.2	563	8.8	106	1.7
AUG-2023	7577	6417	1313	20.5	1663	25.9	557	8.7	107	1.7
SEP-2023	7579	6402	1304	20.4	1644	25.7	557	8.7	104	1.6
OCT-2023	7579	6390	1307	20.5	1647	25.8	552	8.6	99	1.6
NOV-2023	7578	6384	1307	20.5	1643	25.7	558	8.7	101	1.6
DEC-2023	7574	6370	1306	20.5	1633	25.6	553	8.7	100	1.6
JAN-2024	7613	6395	1306	20.4	1644	25.7	549	8.6	102	1.6
FEB-2024	7620	6405	1301	20.3	1646	25.7	562	8.8	102	1.6
MAR-2024	7616	6389	1294	20.3	1637	25.6	555	8.7	105	1.6
APR-2024	7647	6407	1299	20.3	1636	25.5	563	8.8	102	1.6
MAY-2024	7666	6415	1301	20.3	1636	25.5	566	8.8	103	1.6
JUN-2024	7678	6415	1306	20.4	1625	25.3	560	8.7	101	1.6
JUL-2024	7697	6421	1315	20.5	1635	25.5	557	8.7	107	1.7
AUG-2024	7686	6406	1304	20.4	1619	25.3	547	8.5	105	1.6
SEP-2024	7674	6387	1299	20.3	1621	25.4	553	8.7	102	1.6
OCT-2024	7702	6404	1285	20.1	1617	25.3	555	8.7	99	1.6
NOV-2024	7674	6370	1279	20.1	1613	25.3	544	8.5	97	1.5
DEC-2024	7693	6369	1279	20.1	1600	25.1	541	8.5	101	1.6
JAN-2025	7712	6370	1272	20.0	1587	24.9	529	8.3	105	1.7
FEB-2025	7673	6324	1268	20.1	1574	24.9	530	8.4	106	1.7
MAR-2025	7668	6323	1259	19.9	1560	24.7	531	8.4	108	1.7
APR-2025	7703	6342	1263	19.9	1569	24.7	524	8.3	104	1.6
MAY-2025	7677	6319	1265	20.0	1561	24.7	529	8.4	104	1.7

On Antiretroviral (ARV) Treatment: based on dispensing data, participants with a record of ARV medication in the specified month and not deceased or moved out of program.

Ever Tested: those on ARV treatment, with at least one ARV resistance test on record in BC, up until the month of interest.

n: number of participants on ARV treatment who were ever tested for ARV resistance with drug resistance to ≥ 1 drug in the corresponding drug class in BC. Participants may have resistance to none or 1 or more drug class(es).

% is calculated as ratio of "n" and number of participants on ARV treatment who were ever tested for ARV resistance with drug resistance to ≥ 1 drug the corresponding drug class in BC.


Resistance interpretations are performed using the Stanford University HIV Drug Resistance Database Algorithm (HIVdb) version 9.8. HIVdb scores ≥ 15 are classified as "resistant".

INSTI: Integrase Inhibitor, **PI:** Protease Inhibitor, **NNRTI:** Non-Nucleoside Analogue Reverse Transcriptase Inhibitor,

N(t)RTI: Nucleos(t)ide Analogue Reverse Transcriptase Inhibitor



1.24 Active Participants by number of Antiretroviral Drug Classes with Resistance
May 2020 - May 2025



1.25 Active Participants by number of Antiretroviral Drug Classes with Resistance

MON-YYYY	On Antiretroviral Treatment	Ever Tested	0-Class (Wild Type)		1-Class		2-Class		3 or more Class	
			n	%	n	%	n	%	n	%
JUN-2023	7577	6441	4109	63.8	1294	20.1	761	11.8	277	4.3
JUL-2023	7555	6417	4084	63.6	1289	20.1	765	11.9	279	4.4
AUG-2023	7577	6417	4094	63.8	1286	20.0	761	11.9	276	4.3
SEP-2023	7579	6402	4095	64.0	1280	20.0	755	11.8	272	4.3
OCT-2023	7579	6390	4083	63.9	1281	20.1	758	11.9	268	4.2
NOV-2023	7578	6384	4073	63.8	1287	20.2	754	11.8	270	4.2
DEC-2023	7574	6370	4067	63.9	1286	20.2	749	11.8	268	4.2
JAN-2024	7613	6395	4084	63.9	1292	20.2	751	11.7	268	4.2
FEB-2024	7620	6405	4095	63.9	1284	20.1	755	11.8	271	4.2
MAR-2024	7616	6389	4093	64.1	1276	20.0	749	11.7	271	4.2
APR-2024	7647	6407	4100	64.0	1291	20.2	743	11.6	273	4.3
MAY-2024	7666	6415	4104	64.0	1291	20.1	749	11.7	271	4.2
JUN-2024	7678	6415	4114	64.1	1285	20.0	743	11.6	273	4.3
JUL-2024	7697	6421	4107	64.0	1293	20.1	746	11.6	275	4.3
AUG-2024	7686	6406	4112	64.2	1287	20.1	737	11.5	270	4.2
SEP-2024	7674	6387	4095	64.1	1285	20.1	735	11.5	272	4.3
OCT-2024	7702	6404	4117	64.3	1287	20.1	734	11.5	266	4.2
NOV-2024	7674	6370	4095	64.3	1281	20.1	732	11.5	262	4.1
DEC-2024	7693	6369	4101	64.4	1276	20.0	733	11.5	259	4.1
JAN-2025	7712	6370	4112	64.6	1276	20.0	731	11.5	251	3.9
FEB-2025	7673	6324	4075	64.4	1273	20.1	724	11.5	252	4.0
MAR-2025	7668	6323	4083	64.6	1275	20.2	715	11.3	250	4.0
APR-2025	7703	6342	4101	64.7	1274	20.1	718	11.3	249	3.9
MAY-2025	7677	6319	4079	64.6	1273	20.2	718	11.4	249	3.9

Number of Antiretroviral (ARV) Drug Classes with Resistance considers N(t)RTIs, NNRTIs, PIs, and INSTIs only, based on cumulative resistance tests performed in BC (until the specified month) for participants ever tested (see definition below).

Resistance interpretations are performed using the Stanford University HIV Drug Resistance Database Algorithm (HIVdb) version 9.8.

HIVdb scores ≥ 15 are classified as "resistant".

On Antiretroviral Treatment: based on dispensing data, participants with a record of ARV medication in the specified month and not deceased or moved out of program.

Ever tested: those on ARV treatment, with at least one ARV resistance test on record in BC, up until the specified month.





2.1 Active participants by Year of Program Initiation (1987 - 2025) - as of May 2025

DTP Start Year	Duration (years) Median	First Starts	All	Male	Female	Age		(n)	CD4 (cells/ μ L)		(n)	pVL (copies/mL)	
						Median	(Q1, Q3)		Median	(Q1, Q3)		Median	(Q1, Q3)
Pre-1993	31	48	184	175	9	34	(30, 39)	92	550	(388, 753)	170	<40	(<40, <40)
1993	30	121	122	108	14	34	(29, 39)	72	610	(410, 823)	113	<40	(<40, <40)
1994	29	69	69	59	10	35	(30, 38)	44	665	(400, 915)	63	<40	(<40, <40)
1995	28	125	126	107	19	34	(29, 39)	76	620	(425, 770)	111	<40	(<40, <40)
1996	26	316	318	277	41	35	(30, 39)	184	615	(438, 823)	281	<40	(<40, <40)
1997	24	261	267	242	25	34	(30, 38)	162	620	(390, 858)	233	<40	(<40, <40)
1998	24	186	195	162	33	34	(30, 40)	130	570	(413, 780)	178	<40	(<40, <40)
1999	23	167	168	131	37	36	(31, 42)	113	590	(400, 860)	156	<40	(<40, <40)
2000	24	121	124	101	23	38	(33, 44)	77	640	(370, 760)	107	<40	(<40, <40)
2001	23	117	119	96	23	37	(31, 44)	73	670	(400, 820)	111	<40	(<40, <40)
2002	22	118	128	109	19	40	(30, 46)	76	540	(410, 740)	115	<40	(<40, <40)
2003	22	141	151	128	23	39	(34, 46)	97	580	(433, 790)	130	<40	(<40, <40)
2004	21	144	165	129	36	39	(34, 44)	109	640	(420, 840)	153	<40	(<40, <40)
2005	20	185	201	161	40	40	(35, 47)	141	620	(440, 845)	178	<40	(<40, <40)
2006	19	175	194	158	36	41	(33, 48)	134	603	(451, 790)	166	<40	(<40, <40)
2007	18	230	249	217	32	41	(35, 46)	170	673	(473, 860)	226	<40	(<40, <40)
2008	17	270	304	249	55	42	(34, 48)	216	680	(490, 883)	257	<40	(<40, <40)
2009	16	296	329	269	60	41	(35, 47)	216	650	(458, 900)	296	<40	(<40, <40)
2010	15	255	293	231	62	40	(32, 46)	207	650	(473, 825)	252	<40	(<40, <40)
2011	14	314	358	296	62	41	(33, 48)	229	710	(490, 910)	313	<40	(<40, <40)
2012	13	276	312	251	61	41	(32, 49)	195	750	(540, 1010)	278	<40	(<40, <40)
2013	12	249	294	234	60	40	(32, 48)	193	700	(470, 920)	249	<40	(<40, <40)
2014	11	225	298	256	42	40	(31, 50)	192	745	(538, 980)	257	<40	(<40, <40)
2015	10	198	283	239	44	41	(31, 51)	192	700	(488, 900)	249	<40	(<40, <40)
2016	9	180	254	209	45	38	(32, 49)	165	670	(480, 920)	214	<40	(<40, <40)
2017	8	159	225	194	31	36	(28, 45)	158	680	(510, 928)	209	<40	(<40, <40)
2018	7	137	207	163	44	39	(31, 48)	141	780	(560, 980)	179	<40	(<40, <40)
2019	6	132	246	207	39	38	(29, 48)	187	730	(490, 935)	215	<40	(<40, <40)
2020	5	106	202	154	48	37	(31, 48)	149	760	(530, 960)	164	<40	(<40, <40)

Duration defined as cumulative years on antiretroviral treatment, excluding periods of treatment interruption
 CD4 and pVL tests defined as most recent test done in the last 12 months and last 6 months, respectively





2.1 Active participants by Year of Program Initiation (1987 - 2025) - as of May 2025 (cont.)

DTP Start Year	Duration (years) Median	First Starts	All	Male	Female	Age		(n)	CD4 (cells/ μ L)		(n)	pVL (copies/mL)	
						Median	(Q1, Q3)		Median	(Q1, Q3)		Median	(Q1, Q3)
2021	4	107	199	169	30	37	(30, 46)	172	650	(470, 870)	141	<40	(<40, <40)
2022	3	106	269	220	49	38	(31, 47)	244	700	(550, 940)	205	<40	(<40, <40)
2023	2	110	312	255	57	36	(30, 46)	287	640	(453, 828)	238	<40	(<40, <40)
2024	1	137	359	287	72	36	(29, 45)	340	610	(440, 830)	314	<40	(<40, <40)
2025	0	63	153	113	40	36	(29, 45)	149	570	(340, 750)	141	<40	(<40, 149)
Total:		5844	7677	6356	1321								

Duration defined as cumulative years on antiretroviral treatment, excluding periods of treatment interruption
CD4 and pVL tests defined as most recent test done in the last 12 months and last 6 months, respectively



2.2 HIV Viral Load (copies/mL) and CD4 (cells/ μ L) for Participants on Antiretroviral Treatment

MON-YYYY	Total Participants	Median # of Treatment days	(n)	CD4 (cells/ μ L)		(n)	pVL (copies/mL)	
				Median	(Q1, Q3)		Median	(Q1, Q3)
JUN-2023	7599	787	5591	640	(450, 860)	6919	<40	(<40, <40)
JUL-2023	7577	805	5549	650	(450, 860)	6938	<40	(<40, <40)
AUG-2023	7600	804	5524	641	(450, 860)	6890	<40	(<40, <40)
SEP-2023	7609	796	5485	650	(450, 860)	6893	<40	(<40, <40)
OCT-2023	7610	803	5455	640	(450, 860)	6812	<40	(<40, <40)
NOV-2023	7612	795	5405	640	(450, 860)	6841	<40	(<40, <40)
DEC-2023	7603	798	5387	650	(460, 860)	6829	<40	(<40, <40)
JAN-2024	7642	792	5362	640	(460, 860)	6815	<40	(<40, <40)
FEB-2024	7647	781	5329	650	(460, 870)	6865	<40	(<40, <40)
MAR-2024	7636	790	5326	640	(450, 870)	6872	<40	(<40, <40)
APR-2024	7670	786	5310	640	(450, 870)	6843	<40	(<40, <40)
MAY-2024	7687	787	5318	650	(460, 880)	6897	<40	(<40, <40)
JUN-2024	7687	784	5305	650	(460, 870)	6922	<40	(<40, <40)
JUL-2024	7718	786	5334	650	(460, 870)	7010	<40	(<40, <40)
AUG-2024	7709	782	5311	650	(460, 870)	6938	<40	(<40, <40)
SEP-2024	7697	791	5303	650	(460, 870)	6905	<40	(<40, <40)
OCT-2024	7725	787	5314	650	(460, 870)	6899	<40	(<40, <40)
NOV-2024	7703	793	5308	650	(460, 880)	6876	<40	(<40, <40)
DEC-2024	7720	796	5326	650	(460, 880)	6914	<40	(<40, <40)
JAN-2025	7739	792	5331	650	(450, 880)	6883	<40	(<40, <40)
FEB-2025	7696	800	5304	650	(460, 880)	6871	<40	(<40, <40)
MAR-2025	7689	792	5287	650	(450, 875)	6813	<40	(<40, <40)
APR-2025	7719	779	5299	660	(460, 880)	6891	<40	(<40, <40)
MAY-2025	7705	787	5249	660	(460, 880)	6861	<40	(<40, <40)

Active participant defined as being on antiretroviral treatment in the specified month

Treatment days defined as number of consecutive days on antiretroviral treatment (most recent uninterrupted period)

CD4 and pVL tests defined as tests done in the specified month





2.3 BC-CfE HIV Treatment Program Enrolment

MON-YYYY	On ARV Treatment	Off ARV Treatment	Deceased	ARV Treatment naïve starts	ARV Treatment experienced starts	Newly interrupted ARV Treatment	Net Change
JUN-2023	7577	697	14	17	168	165	3
JUL-2023	7555	728	11	11	164	181	-22
AUG-2023	7577	727	11	13	217	192	22
SEP-2023	7579	714	14	5	179	163	2
OCT-2023	7579	724	18	10	170	160	0
NOV-2023	7578	731	18	9	182	171	-1
DEC-2023	7574	740	14	13	169	169	-4
JAN-2024	7613	698	16	11	204	159	39
FEB-2024	7620	695	17	11	184	165	7
MAR-2024	7616	709	12	13	183	185	-4
APR-2024	7647	692	17	20	197	168	31
MAY-2024	7666	691	12	16	191	173	19
JUN-2024	7678	706	5	23	173	177	12
JUL-2024	7697	695	15	10	185	159	19
AUG-2024	7686	710	13	15	164	168	-11
SEP-2024	7674	716	9	7	182	186	-12
OCT-2024	7702	709	8	15	200	172	28
NOV-2024	7674	746	14	9	181	199	-28
DEC-2024	7693	743	15	10	194	170	19
JAN-2025	7712	716	14	14	196	170	19
FEB-2025	7673	759	10	9	166	201	-39
MAR-2025	7668	759	12	12	175	177	-5
APR-2025	7703	736	9	12	193	157	35
MAY-2025	7677	757	18	17	167	188	-26

ARV: antiretroviral

On ARV Treatment: based on dispensing data, participants with a record of ARV medication in the specified month and not deceased or moved out of program

Off ARV Treatment: based on dispensing data, participants with no record of ARV medication in the specified month and not deceased or moved out of program

Deceased: in the specified month, and on ARV treatment in the previous month

ARV Treatment naïve starts: participants starting ARV treatment in the specified month for the first time


ARV Treatment experienced starts: participants with history of ARV treatment, but first dispensing in the BC HIV Treatment Program in the specified month

Newly Interrupted ARV Treatment: based on dispensing data, participants with no record of ARV medication in the specified month, but had a record of ARV medication in the previous month, and not deceased or moved out of program, and had contact with the program in the past 5 years.

Net Change: the difference between ARV treatment starts (naïve and experienced) and ARV treatment stops (Deceased, moved out of program, or newly interrupted ARV treatment)




3.1 Distribution of HIV Treatment Program Active Participants
May 2025






3.2 Distribution of HIV Treatment Program Active Participants May 2025

INTERIOR HEALTH AUTHORITY BY HEALTH SERVICE DELIVERY AREA/LOCAL HEALTH AREA




KELOWNA BY POSTAL CODE






3.3 Distribution of HIV Treatment Program Active Participants May 2025

FRASER HEALTH AUTHORITY BY HEALTH SERVICE DELIVERY AREA/LOCAL HEALTH AREA




SURREY BY POSTAL CODE




3.4 Distribution of HIV Treatment Program Active Participants
May 2025

VANCOUVER COASTAL HEALTH AUTHORITY BY HEALTH SERVICE DELIVERY AREA/LOCAL HEALTH AREA



VANCOUVER BY POSTAL CODE




*** Please refer to VIHA (432 and 434) on the next page






3.5 Distribution of HIV Treatment Program Active Participants May 2025

VANCOUVER ISLAND HEALTH AUTHORITY BY HEALTH SERVICE DELIVERY AREA/LOCAL HEALTH AREA




VICTORIA BY POSTAL CODE






3.6 Distribution of HIV Treatment Program Active Participants
May 2025

NORTHERN HEALTH AUTHORITY BY HEALTH SERVICE DELIVERY AREA/LOCAL HEALTH AREA



PRINCE GEORGE BY POSTAL CODE



4.1 Distribution of Participants by Age & Sex at Birth INTERIOR Health Authority (HA)

Health Service Delivery Area	Age Group	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
EAST KOOTENAY	0 - 29	*	*	0	0	N/A	0	N/A
	30 - 49	*	*	0	14	815	13	<40
	50 - 64	*	*	0	13	720	11	<40
	65+	*	*	0	6	590	5	<40
	Total HSDA:	37	32	0	33	760	29	<40
KOOTENAY BOUNDARY	0 - 29	5	5	0	5	880	*	*
	30 - 49	14	13	0	12	765	*	*
	50 - 64	21	16	0	17	560	*	*
	65+	18	18	0	13	740	*	*
	Total HSDA:	58	52	0	47	760	46	<40
OKANAGAN	0 - 29	15	14	*	15	730	13	<40
	30 - 49	124	117	*	115	710	93	<40
	50 - 64	164	153	*	144	675	129	<40
	65+	82	80	*	77	540	71	<40
	Total HSDA:	385	364	<5	351	650	306	<40
THOMPSON/CARIBOO/SHUSWAP	0 - 29	15	11	0	11	600	10	<40
	30 - 49	57	49	0	45	740	38	<40
	50 - 64	87	77	0	69	680	67	<40
	65+	36	36	0	30	695	30	<40
	Total HSDA:	195	173	0	155	690	145	<40
Total HA:		675	621	<5	586	680	526	<40

	Age Group	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
	0 - 29	36	31	*	31	780	26	<40
	30 - 49	210	190	*	186	740	156	<40
	50 - 64	286	260	*	243	680	221	<40
	65+	143	140	*	126	610	123	<40
Total HA:		675	621	<5	586	680	526	<40

Sex at Birth	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
Male	543	503	*	469	660	431	<40
Female	132	118	*	117	760	95	<40
Unknown	0	0	*	0	N/A	0	N/A

Currently on antiretroviral treatment	# of Participants	Median Age	Median CD4	Median pVL
Total HA:	621	56	680	<40

* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

Enrolled: Participants who had enrolled in the HIV Treatment Program, but not known to be deceased or formally reported as moved out of program
 # **on ART**: # of participants on antiretroviral treatment (ART) in the specified month based on dispensing record
 # **CD4** or **pVL** tested: participants tested for CD4 or pVL within the past 12 months and 6 months, respectively (CD4 in cells/μL and pVL in copies/mL)



4.2 Distribution of Participants by Program Duration INTERIOR Health Authority

HSDA	Program Duration	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
EAST KOOTENAY	10 years or more	17	14	0	16	710	13	<40
	5 years or more	11	11	0	7	870	9	<40
	<5 years	9	7	0	10	830	7	<40
	Never on ART	0	0	0	0	N/A	0	N/A
	Total HSDA:	37	32	0	33	760	29	<40
KOOTENAY BOUNDARY	10 years or more	43	38	0	34	705	*	*
	5 years or more	7	6	0	5	780	*	*
	<5 years	8	8	0	8	755	*	*
	Never on ART	0	0	0	0	N/A	*	*
	Total HSDA:	58	52	0	47	760	46	<40
OKANAGAN	10 years or more	245	235	*	219	660	194	<40
	5 years or more	60	55	*	54	675	48	<40
	<5 years	80	74	*	78	620	64	<40
	Never on ART	0	0	*	0	N/A	0	N/A
	Total HSDA:	385	364	<5	351	650	306	<40
THOMPSON/CARIBOO/SHUSWAP	10 years or more	123	109	0	101	680	90	<40
	5 years or more	25	20	0	15	810	17	<40
	<5 years	47	44	0	39	600	38	<40
	Never on ART	0	0	0	0	N/A	0	N/A
	Total HSDA:	195	173	0	155	690	145	<40
Total HA:		675	621	<5	586	680	526	<40

	Program Duration	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
	10 years or more	428	396	*	370	680	333	<40
	5 years or more	103	92	*	81	720	77	<40
	<5 years	144	133	*	135	650	116	<40
	Never on ART	0	0	*	0	N/A	0	N/A
Total HA:		675	621	<5	586	680	526	<40

* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

Enrolled: Participants who had enrolled in HIV Treatment Program, not known to be deceased or formally reported as moved out of program

on ART: Participants on antiretroviral treatment (ART) in the specified month based on dispensing record (as above footnote)

Program Duration: years since first antiretroviral treatment dispensing in BC HIV Treatment Program

CD4 or pVL tested: participants tested for CD4 or pVL within the past 12 months and 6 months, respectively





4.3 Distribution of Antiretroviral Treatment Prescribers INTERIOR Health Authority

HSDA of Prescriber Residency	# of Prescribers currently prescribing Antiretroviral Treatment	# of Participants currently treated by Prescribers	# of Prescribers ever prescribed Antiretroviral Treatment	# of Participants ever treated by Prescribers
EAST KOOTENAY	13	32	53	103
KOOTENAY BOUNDARY	20	41	78	141
OKANAGAN	53	335	245	1115
THOMPSON/CARIBOO/SHUSWAP	30	142	152	594
Total:	116	550	528	1953

HSDA of Participant Residency	# of Participants with Prescriber out of HA/HSDA
EAST KOOTENAY	*
KOOTENAY BOUNDARY	*
OKANAGAN	*
THOMPSON/CARIBOO/SHUSWAP	*
Total:	132

* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

Currently prescribing Antiretroviral Treatment: number of prescribers of antiretroviral treatment dispensed in the previous 6 months (based on participant HA/HSDA)

Currently treated: number of participants with antiretroviral treatment dispensed in the previous 6 months by antiretroviral treatment prescribers (based on follow-up prescriber HA/HSDA)

Prescribers ever prescribed Antiretroviral Treatment: for participants residing in HA/HSDA

Participants ever treated by prescribers: where follow-up prescriber is in the HA/HSDA

Participants with Prescriber out of HA/HSDA: participants residing in specified HA/HSDA with follow-up prescriber(s) in another HA/HSDA



4.4 Distribution of Participants by Age & Sex at Birth FRASER Health Authority (HA)

Health Service Delivery Area	Age Group	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
FRASER EAST	0 - 29	28	25	*	30	745	30	<40
	30 - 49	114	97	*	86	706.5	94	<40
	50 - 64	157	143	*	105	590	134	<40
	65+	72	70	*	49	740	66	<40
	Total HSDA:	371	335	<5	270	672.5	324	<40
FRASER NORTH	0 - 29	51	44	*	46	580	47	<40
	30 - 49	376	329	*	300	710	316	<40
	50 - 64	353	332	*	235	690	308	<40
	65+	176	168	*	108	620	155	<40
	Total HSDA:	956	873	<5	689	680	826	<40
FRASER SOUTH	0 - 29	69	65	*	59	600	64	<40
	30 - 49	352	322	*	250	695	311	<40
	50 - 64	395	368	*	253	630	338	<40
	65+	164	159	*	117	560	151	<40
	Total HSDA:	980	914	<5	679	640	864	<40
Total HA:		2307	2122	6	1638	660	2014	<40

	Age Group	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
	0 - 29	148	134	*	135	630	141	<40
	30 - 49	842	748	*	636	700	721	<40
	50 - 64	905	843	*	593	650	780	<40
	65+	412	397	*	274	600	372	<40
Total HA:		2307	2122	6	1638	660	2014	<40

Sex at Birth	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
Male	1742	1616	*	1188	649.5	1530	<40
Female	565	506	*	450	700	484	<40
Unknown	0	0	*	0	N/A	0	N/A

Currently on antiretroviral treatment	# of Participants	Median Age	Median CD4	Median pVL
Total HA:	2122	53	670	<40

* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

Enrolled: Participants who had enrolled in the HIV Treatment Program, but not known to be deceased or formally reported as moved out of program
 # **on ART**: # of participants on antiretroviral treatment (ART) in the specified month based on dispensing record
 # **CD4** or **pVL** tested: participants tested for CD4 or pVL within the past 12 months and 6 months, respectively (CD4 in cells/ μ L and pVL in copies/mL)



4.5 Distribution of Participants by Program Duration FRASER Health Authority

HSDA	Program Duration	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
FRASER EAST	10 years or more	236	217	*	*	*	*	*
	5 years or more	58	44	*	*	*	*	*
	<5 years	77	74	*	*	*	*	*
	Never on ART	0	0	*	*	*	*	*
	Total HSDA:	371	335	<5	270	672.5	324	<40
FRASER NORTH	10 years or more	593	551	*	399	700	*	*
	5 years or more	166	147	*	126	715	*	*
	<5 years	197	175	*	164	615	*	*
	Never on ART	0	0	*	0	N/A	*	*
	Total HSDA:	956	873	<5	689	680	826	<40
FRASER SOUTH	10 years or more	570	526	*	*	*	*	*
	5 years or more	169	153	*	*	*	*	*
	<5 years	241	235	*	*	*	*	*
	Never on ART	0	0	*	*	*	*	*
	Total HSDA:	980	914	<5	679	640	864	<40
Total HA:		2307	2122	6	1638	660	2014	<40

	Program Duration	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
	10 years or more	1399	1294	0	941	680	1205	<40
	5 years or more	393	344	0	268	665	321	<40
	<5 years	515	484	6	422	630	480	<40
	Never on ART	0	0	0	7	550	8	309
Total HA:		2307	2122	6	1638	660	2014	<40

* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

Enrolled: Participants who had enrolled in HIV Treatment Program, not known to be deceased or formally reported as moved out of program

on ART: Participants on antiretroviral treatment (ART) in the specified month based on dispensing record (as above footnote)

Program Duration: years since first antiretroviral treatment dispensing in BC HIV Treatment Program

CD4 or pVL tested: participants tested for CD4 or pVL within the past 12 months and 6 months, respectively





4.6 Distribution of Antiretroviral Treatment Prescribers FRASER Health Authority

HSDA of Prescriber Residency	# of Prescribers currently prescribing Antiretroviral Treatment	# of Participants currently treated by Prescribers	# of Prescribers ever prescribed Antiretroviral Treatment	# of Participants ever treated by Prescribers
FRASER EAST	29	64	154	555
FRASER NORTH	28	242	268	1659
FRASER SOUTH	43	553	238	1975
Total:	100	859	660	4189

HSDA of Participant Residency	# of Participants with Prescriber out of HA/HSDA
FRASER EAST	220
FRASER NORTH	725
FRASER SOUTH	476
Total:	1421

* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

Currently prescribing Antiretroviral Treatment: number of prescribers of antiretroviral treatment dispensed in the previous 6 months (based on participant HA/HSDA)

Currently treated: number of participants with antiretroviral treatment dispensed in the previous 6 months by antiretroviral treatment prescribers (based on follow-up prescriber HA/HSDA)

Prescribers ever prescribed Antiretroviral Treatment: for participants residing in HA/HSDA

Participants ever treated by prescribers: where follow-up prescriber is in the HA/HSDA

Participants with Prescriber out of HA/HSDA: participants residing in specified HA/HSDA with follow-up prescriber(s) in another HA/HSDA



4.7 Distribution of Participants by Age & Sex at Birth VANCOUVER COASTAL Health Authority (HA)

Health Service Delivery Area	Age Group	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
NORTH SHORE/COAST GARIBALDI	0 - 29	10	9	0	9	920	8	<40
	30 - 49	78	70	0	58	700	66	<40
	50 - 64	132	123	0	82	745	106	<40
	65+	96	89	0	74	660	78	<40
	Total HSDA:	316	291	0	223	700	258	<40
RICHMOND	0 - 29	11	9	0	11	610	8	<40
	30 - 49	63	58	0	54	625	55	<40
	50 - 64	76	72	0	59	690	72	<40
	65+	29	29	0	25	550	28	<40
	Total HSDA:	179	168	0	149	640	163	<40
VANCOUVER	0 - 29	108	99	*	93	750	96	<40
	30 - 49	1146	1007	*	832	690	969	<40
	50 - 64	1499	1377	*	1023	600	1328	<40
	65+	734	700	*	459	630	688	<40
	Total HSDA:	3487	3183	7	2407	640	3081	<40
Total HA:		3982	3642	7	2779	650	3502	<40

	Age Group	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
	0 - 29	129	117	*	113	750	112	<40
	30 - 49	1287	1135	*	944	690	1090	<40
	50 - 64	1707	1572	*	1164	620	1506	<40
	65+	859	818	*	558	630	794	<40
Total HA:		3982	3642	7	2779	650	3502	<40

Sex at Birth	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
Male	3490	3197	7	2320	650	3082	<40
Female	492	445	0	459	660	420	<40
Unknown	0	0	0	0	N/A	0	N/A

Currently on antiretroviral treatment	# of Participants	Median Age	Median CD4	Median pVL
Total HA:	3642	56	650	<40

* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

Enrolled: Participants who had enrolled in the HIV Treatment Program, but not known to be deceased or formally reported as moved out of program
 # **on ART**: # of participants on antiretroviral treatment (ART) in the specified month based on dispensing record
 # **CD4** or **pVL** tested: participants tested for CD4 or pVL within the past 12 months and 6 months, respectively (CD4 in cells/ μ L and pVL in copies/mL)



4.8 Distribution of Participants by Program Duration VANCOUVER COASTAL Health Authority

HSDA	Program Duration	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
NORTH SHORE/COAST GARIBALDI	10 years or more	228	208	0	*	*	182	<40
	5 years or more	44	43	0	*	*	39	<40
	<5 years	44	40	0	*	*	37	<40
	Never on ART	0	0	0	*	*	0	N/A
	Total HSDA:	316	291	0	223	700	258	<40
RICHMOND	10 years or more	102	97	0	78	650	94	<40
	5 years or more	34	29	0	28	625	27	<40
	<5 years	43	42	0	43	620	42	<40
	Never on ART	0	0	0	0	N/A	0	N/A
	Total HSDA:	179	168	0	149	640	163	<40
VANCOUVER	10 years or more	2432	2255	0	1614	620	2174	<40
	5 years or more	558	478	0	369	730	453	<40
	<5 years	497	450	7	418	670	449	<40
	Never on ART	0	0	0	6	775	5	<40
	Total HSDA:	3487	3183	7	2407	640	3081	<40
Total HA:		3982	3642	7	2779	650	3502	<40

	Program Duration	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
	10 years or more	2762	2560	0	1845	630	2450	<40
	5 years or more	636	550	0	428	730	519	<40
	<5 years	584	532	7	499	660	528	<40
	Never on ART	0	0	0	7	850	5	<40
Total HA:		3982	3642	7	2779	650	3502	<40

* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

Enrolled: Participants who had enrolled in HIV Treatment Program, not known to be deceased or formally reported as moved out of program

on ART: Participants on antiretroviral treatment (ART) in the specified month based on dispensing record (as above footnote)

Program Duration: years since first antiretroviral treatment dispensing in BC HIV Treatment Program

CD4 or pVL tested: participants tested for CD4 or pVL within the past 12 months and 6 months, respectively





4.9 Distribution of Antiretroviral Treatment Prescribers VANCOUVER COASTAL Health Authority

HSDA of Prescriber Residency	# of Prescribers currently prescribing Antiretroviral Treatment	# of Participants currently treated by Prescribers	# of Prescribers ever prescribed Antiretroviral Treatment	# of Participants ever treated by Prescribers
NORTH SHORE/COAST GARIBALDI	36	59	201	580
RICHMOND	9	109	49	341
VANCOUVER	201	5402	699	12218
Total:	246	5570	949	13139

HSDA of Participant Residency	# of Participants with Prescriber out of HA/HSDA
NORTH SHORE/COAST GARIBALDI	*
RICHMOND	*
VANCOUVER	*
Total:	58

* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

Currently prescribing Antiretroviral Treatment: number of prescribers of antiretroviral treatment dispensed in the previous 6 months (based on participant HA/HSDA)

Currently treated: number of participants with antiretroviral treatment dispensed in the previous 6 months by antiretroviral treatment prescribers (based on follow-up prescriber HA/HSDA)

Prescribers ever prescribed Antiretroviral Treatment: for participants residing in HA/HSDA

Participants ever treated by prescribers: where follow-up prescriber is in the HA/HSDA

Participants with Prescriber out of HA/HSDA: participants residing in specified HA/HSDA with follow-up prescriber(s) in another HA/HSDA



4.10 Distribution of Participants by Age & Sex at Birth VANCOUVER ISLAND Health Authority (HA)

Health Service Delivery Area	Age Group	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
CENTRAL VANCOUVER ISLAND	0 - 29	8	7	0	5	810	6	<40
	30 - 49	82	76	0	54	655	73	<40
	50 - 64	144	134	0	74	705	114	<40
	65+	87	82	0	42	520	76	<40
	Total HSDA:	321	299	0	175	600	269	<40
NORTH VANCOUVER ISLAND	0 - 29	5	*	0	*	*	5	<40
	30 - 49	28	*	0	*	*	17	<40
	50 - 64	55	*	0	*	*	36	<40
	65+	34	*	0	*	*	28	<40
	Total HSDA:	122	117	0	65	650	86	<40
SOUTH VANCOUVER ISLAND	0 - 29	30	25	*	13	510	22	<40
	30 - 49	207	178	*	74	620	162	<40
	50 - 64	314	293	*	97	650	249	<40
	65+	162	156	*	34	690	142	<40
	Total HSDA:	713	652	<5	218	650	575	<40
Total HA:		1156	1068	<5	458	640	930	<40

	Age Group	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
	0 - 29	43	36	*	22	585	33	<40
	30 - 49	317	281	*	147	640	252	<40
	50 - 64	513	481	*	197	660	399	<40
	65+	283	270	*	92	600	246	<40
Total HA:		1156	1068	<5	458	640	930	<40

Sex at Birth	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
Male	964	893	*	358	600	774	<40
Female	192	175	*	100	700	156	<40
Unknown	0	0	*	0	N/A	0	N/A

Currently on antiretroviral treatment	# of Participants	Median Age	Median CD4	Median pVL
Total HA:	1068	57	650	<40

* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

Enrolled: Participants who had enrolled in the HIV Treatment Program, but not known to be deceased or formally reported as moved out of program
 # **on ART**: # of participants on antiretroviral treatment (ART) in the specified month based on dispensing record
 # **CD4** or **pVL** tested: participants tested for CD4 or pVL within the past 12 months and 6 months, respectively (CD4 in cells/ μ L and pVL in copies/mL)





4.11 Distribution of Participants by Program Duration VANCOUVER ISLAND Health Authority

HSDA	Program Duration	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
CENTRAL VANCOUVER ISLAND	10 years or more	217	201	0	107	600	182	<40
	5 years or more	52	48	0	30	720	43	<40
	<5 years	52	50	0	38	550	44	<40
	Never on ART	0	0	0	0	N/A	0	N/A
	Total HSDA:	321	299	0	175	600	269	<40
NORTH VANCOUVER ISLAND	10 years or more	90	86	0	40	620	64	<40
	5 years or more	13	13	0	8	655	7	<40
	<5 years	19	18	0	17	700	15	<40
	Never on ART	0	0	0	0	N/A	0	N/A
	Total HSDA:	122	117	0	65	650	86	<40
SOUTH VANCOUVER ISLAND	10 years or more	433	404	*	*	*	*	*
	5 years or more	133	117	*	*	*	*	*
	<5 years	147	131	*	*	*	*	*
	Never on ART	0	0	*	*	*	*	*
	Total HSDA:	713	652	<5	218	650	575	<40
Total HA:		1156	1068	<5	458	640	930	<40

	Program Duration	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
	10 years or more	740	691	*	*	*	*	*
	5 years or more	198	178	*	*	*	*	*
	<5 years	218	199	*	*	*	*	*
	Never on ART	0	0	*	*	*	*	*
Total HA:		1156	1068	<5	458	640	930	<40

* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

Enrolled: Participants who had enrolled in HIV Treatment Program, not known to be deceased or formally reported as moved out of program

on ART: Participants on antiretroviral treatment (ART) in the specified month based on dispensing record (as above footnote)

Program Duration: years since first antiretroviral treatment dispensing in BC HIV Treatment Program

CD4 or pVL tested: participants tested for CD4 or pVL within the past 12 months and 6 months, respectively





4.12 Distribution of Antiretroviral Treatment Prescribers VANCOUVER ISLAND Health Authority

HSDA of Prescriber Residency	# of Prescribers currently prescribing Antiretroviral Treatment	# of Participants currently treated by Prescribers	# of Prescribers ever prescribed Antiretroviral Treatment	# of Participants ever treated by Prescribers
CENTRAL VANCOUVER ISLAND	70	214	215	982
NORTH VANCOUVER ISLAND	33	66	155	367
SOUTH VANCOUVER ISLAND	48	607	239	2077
Total:	151	887	609	3426

HSDA of Participant Residency	# of Participants with Prescriber out of HA/HSDA
CENTRAL VANCOUVER ISLAND	88
NORTH VANCOUVER ISLAND	50
SOUTH VANCOUVER ISLAND	128
Total:	266

* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

Currently prescribing Antiretroviral Treatment: number of prescribers of antiretroviral treatment dispensed in the previous 6 months (based on participant HA/HSDA)

Currently treated: number of participants with antiretroviral treatment dispensed in the previous 6 months by antiretroviral treatment prescribers (based on follow-up prescriber HA/HSDA)

Prescribers ever prescribed Antiretroviral Treatment: for participants residing in HA/HSDA

Participants ever treated by prescribers: where follow-up prescriber is in the HA/HSDA

Participants with Prescriber out of HA/HSDA: participants residing in specified HA/HSDA with follow-up prescriber(s) in another HA/HSDA



4.13 Distribution of Participants by Age & Sex at Birth NORTHERN Health Authority (HA)

Health Service Delivery Area	Age Group	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
NORTH EAST	0 - 29	*	*	0	*	*	*	*
	30 - 49	*	*	0	*	*	*	*
	50 - 64	*	*	0	*	*	*	*
	65+	*	*	0	*	*	*	*
	Total HSDA:	46	29	0	43	500	34	<40
NORTH WEST	0 - 29	*	*	0	*	*	*	*
	30 - 49	*	*	0	*	*	*	*
	50 - 64	*	*	0	*	*	*	*
	65+	*	*	0	*	*	*	*
	Total HSDA:	74	67	0	63	620	59	<40
NORTHERN INTERIOR	0 - 29	7	6	0	7	710	7	<40
	30 - 49	69	53	0	57	640	47	<40
	50 - 64	69	61	0	67	500	51	<40
	65+	32	27	0	32	555	25	<40
	Total HSDA:	177	147	0	163	570	130	<40
Total HA:		297	243	0	269	590	223	<40

	Age Group	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
	0 - 29	13	9	0	13	700	13	<40
	30 - 49	112	85	0	93	640	76	<40
	50 - 64	123	105	0	115	560	96	<40
	65+	49	44	0	48	515	38	<40
Total HA:		297	243	0	269	590	223	<40

Sex at Birth	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
Male	195	164	0	181	590	155	<40
Female	102	79	0	88	570	68	<40
Unknown	0	0	0	0	N/A	0	N/A

Currently on antiretroviral treatment	# of Participants	Median Age	Median CD4	Median pVL
Total HA:	243	54	590	<40

* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

Enrolled: Participants who had enrolled in the HIV Treatment Program, but not known to be deceased or formally reported as moved out of program
 # **on ART**: # of participants on antiretroviral treatment (ART) in the specified month based on dispensing record
 # **CD4** or **pVL** tested: participants tested for CD4 or pVL within the past 12 months and 6 months, respectively (CD4 in cells/ μ L and pVL in copies/mL)



4.14 Distribution of Participants by Program Duration NORTHERN Health Authority

HSDA	Program Duration	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
NORTH EAST	10 years or more	22	*	0	*	*	*	*
	5 years or more	5	*	0	*	*	*	*
	<5 years	19	*	0	*	*	*	*
	Never on ART	0	*	0	*	*	*	*
	Total HSDA:	46	29	0	43	500	34	<40
NORTH WEST	10 years or more	50	43	0	41	610	37	<40
	5 years or more	9	9	0	7	720	9	<40
	<5 years	15	15	0	15	570	13	<40
	Never on ART	0	0	0	0	N/A	0	N/A
	Total HSDA:	74	67	0	63	620	59	<40
NORTHERN INTERIOR	10 years or more	113	95	0	*	*	*	*
	5 years or more	38	30	0	*	*	*	*
	<5 years	26	22	0	*	*	*	*
	Never on ART	0	0	0	*	*	*	*
	Total HSDA:	177	147	0	163	570	130	<40
Total HA:		297	243	0	269	590	223	<40

	Program Duration	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
	10 years or more	185	152	0	*	*	*	*
	5 years or more	52	41	0	*	*	*	*
	<5 years	60	50	0	*	*	*	*
	Never on ART	0	0	0	*	*	*	*
Total HA:		297	243	0	269	590	223	<40

* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

Enrolled: Participants who had enrolled in HIV Treatment Program, not known to be deceased or formally reported as moved out of program

on ART: Participants on antiretroviral treatment (ART) in the specified month based on dispensing record (as above footnote)

Program Duration: years since first antiretroviral treatment dispensing in BC HIV Treatment Program

CD4 or pVL tested: participants tested for CD4 or pVL within the past 12 months and 6 months, respectively





4.15 Distribution of Antiretroviral Treatment Prescribers NORTHERN Health Authority

HSDA of Prescriber Residency	# of Prescribers currently prescribing Antiretroviral Treatment	# of Participants currently treated by Prescribers	# of Prescribers ever prescribed Antiretroviral Treatment	# of Participants ever treated by Prescribers
NORTH EAST	2	*	37	50
NORTH WEST	15	*	93	176
NORTHERN INTERIOR	22	*	129	555
Total:	39	232	259	781

HSDA of Participant Residency	# of Participants with Prescriber out of HA/HSDA
NORTH EAST	7
NORTH WEST	29
NORTHERN INTERIOR	24
Total:	60

* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

Currently prescribing Antiretroviral Treatment: number of prescribers of antiretroviral treatment dispensed in the previous 6 months (based on participant HA/HSDA)

Currently treated: number of participants with antiretroviral treatment dispensed in the previous 6 months by antiretroviral treatment prescribers (based on follow-up prescriber HA/HSDA)

Prescribers ever prescribed Antiretroviral Treatment: for participants residing in HA/HSDA

Participants ever treated by prescribers: where follow-up prescriber is in the HA/HSDA

Participants with Prescriber out of HA/HSDA: participants residing in specified HA/HSDA with follow-up prescriber(s) in another HA/HSDA



4.16 Distribution of Indigenous Participants by Health Service Delivery Area and Sex at Birth

HA	HSDA	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
INTERIOR	EAST KOOTENAY	*	*	0	*	*	*	*
	KOOTENAY BOUNDARY	*	*	0	*	*	*	*
	OKANAGAN	*	*	0	*	*	*	*
	THOMPSON/CARIBOO/SHUSWAP	*	*	0	*	*	*	*
	Total HA:	53	45	0	43	550	40	<40
FRASER	FRASER EAST	31	28	0	26	615	26	<40
	FRASER NORTH	39	34	0	30	480	30	<40
	FRASER SOUTH	63	57	0	40	564	47	<40
	Total HA:	133	119	0	96	546	103	<40
VANCOUVER COASTAL	NORTH SHORE/COAST GARIBALDI	29	23	0	23	792	20	<40
	RICHMOND	6	6	0	6	775	6	<40
	VANCOUVER	361	332	0	342	470	323	<40
	Total HA:	396	361	0	371	490	349	<40
VANCOUVER ISLAND	CENTRAL VANCOUVER ISLAND	44	39	*	26	550	36	<40
	NORTH VANCOUVER ISLAND	16	14	*	11	440	10	<40
	SOUTH VANCOUVER ISLAND	44	38	*	16	550	36	<40
	Total HA:	104	91	<5	53	550	82	<40
NORTHERN	NORTH EAST	11	7	0	11	450	7	<40
	NORTH WEST	34	30	0	30	550	28	<40
	NORTHERN INTERIOR	64	52	0	59	570	47	<40
	Total HA:	109	89	0	100	560	82	<40
Total:	795	705	<5	663	510	656	<40	

Sex at Birth	# Enrolled	# on Antiretroviral Treatment	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
Male	498	448	*	410	500	412	<40
Female	297	257	*	253	550	244	<40
Unknown	0	0	*	0	N/A	0	N/A

Currently on antiretroviral treatment	# of Participants	Median Age	Median CD4	Median pVL
Total:	705	55	525	<40

* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

Enrolled: Participants who had enrolled in the HIV Treatment Program, but not known to be deceased or formally reported as moved out of program

on Antiretroviral Treatment: defined as # of Participants being on antiretroviral treatment in the specified month

CD4 or pVL tested: participants tested for CD4 or pVL within the past 12 months and 6 months, respectively (CD4 in cells/μL and pVL in copies/mL)





BRITISH COLUMBIA
CENTRE *for* EXCELLENCE
in HIV/AIDS

Funding for the BC Centre for Excellence in HIV/AIDS and HIV Drug Treatment Program provided in-part by:

